SPOTLIGHT: Thailand skirts Plavix patent

Thailand's health ministry has decided to import a generic version of the heart drug Plavix from India, even though the Schering Plough drug is still under patent. Made by M-Cure, the pills will be imported using compulsory licensing, a World Trade Organization waiver that allows developing nations to bypass drug patents when they have no means to pay for branded versions of necessary drugs. Previously, the Thai government had invoked compulsory licensing for two anti-HIV agents. E.U. and U.S. officials protested the Plavix decision. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.